| 9.54 0.73 (8.29%) | 01-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.29 | 1-year : | 13.19 |
| Resists | First : | 9.67 | Second : | 11.29 |
| Pivot price | 8.12  |
|||
| Supports | First : | 7.94 | Second : | 6.88 |
| MAs | MA(5) : | 9.39 |
MA(20) : | 7.9 |
| MA(100) : | 6.79 |
MA(250) : | 8.29 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 95.3 | D(3) : | 95.6 |
| RSI | RSI(14): 82.7 | |||
| 52-week | High : | 13.64 | Low : | 5.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SPNE ] has closed below upper band by 13.2%. Bollinger Bands are 199.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.68 - 9.73 | 9.73 - 9.77 |
| Low: | 8.33 - 8.38 | 8.38 - 8.41 |
| Close: | 9.46 - 9.55 | 9.55 - 9.61 |
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Mon, 22 Apr 2024
SeaSpine Holdings Enters Oversold Territory - Yahoo Lifestyle Australia
Wed, 22 Nov 2023
RSB Spine Sues Orthofix and SeaSpine for Patent Infringement - https://ryortho.com/
Wed, 04 Jan 2023
Orthofix and SeaSpine Announce Completion of Merger of Equals to Create a Leading Global Spine and Orthopedics ... - Business Wire
Tue, 18 Oct 2022
SeaSpine Announces Full Commercial Launch of the 7D FLASH™ Navigation System Percutaneous Spine Module for ... - OrthoSpineNews
Tue, 11 Oct 2022
Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company - Business Wire
Tue, 19 Jul 2022
SeaSpine Announces Three-Year Extension and Expansion of $30 Million Credit Facility - OrthoSpineNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 72.7 (%) |
| Shares Short | 339 (K) |
| Shares Short P.Month | 396 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | -0.58 |
| EPS Est This Year | -2.69 |
| EPS Est Next Year | -2 |
| Book Value (p.s.) | 7.38 |
| Profit Margin | -28.3 % |
| Operating Margin | -25.4 % |
| Return on Assets (ttm) | -9.6 % |
| Return on Equity (ttm) | -21.6 % |
| Qtrly Rev. Growth | 44.5 % |
| Gross Profit (p.s.) | 3.14 |
| Sales Per Share | 6.08 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -5.86 |
| PEG Ratio | 1.1 |
| Price to Book value | 1.29 |
| Price to Sales | 1.56 |
| Price to Cash Flow | -7.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|